Stock Research for MEIP

MEIP

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

MEIP Stock Chart & Research Data

The MEIP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MEIP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


MEIP Due diligence Resources & Stock Charts

The MEIP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MEIP Detailed Price Forecast - CNN Money CNN View MEIP Detailed Summary - Google Finance
Yahoo View MEIP Detailed Summary - Yahoo! Finance Zacks View MEIP Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View MEIP Trends & Analysis - Trade-Ideas Barrons View MEIP Major Holders - Barrons
NASDAQ View MEIP Call Transcripts - NASDAQ Seeking View MEIP Breaking News & Analysis - Seeking Alpha
Spotlight View MEIP Annual Report - CompanySpotlight.com OTC Report View MEIP OTC Short Report - OTCShortReport.com
TradeKing View MEIP Fundamentals - TradeKing Charts View MEIP SEC Filings - Bar Chart
WSJ View Historical Prices for MEIP - The WSJ Morningstar View Performance/Total Return for MEIP - Morningstar
MarketWatch View the Analyst Estimates for MEIP - MarketWatch CNBC View the Earnings History for MEIP - CNBC
StockMarketWatch View the MEIP Earnings - StockMarketWatch MacroAxis View MEIP Buy or Sell Recommendations - MacroAxis
Bullish View the MEIP Bullish Patterns - American Bulls Short Pains View MEIP Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View MEIP Stock Mentions - StockTwits PennyStocks View MEIP Stock Mentions - PennyStockTweets
Twitter View MEIP Stock Mentions - Twitter Invest Hub View MEIP Investment Forum News - Investor Hub
Yahoo View MEIP Stock Mentions - Yahoo! Message Board Seeking Alpha View MEIP Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for MEIP - SECform4.com Insider Cow View Insider Transactions for MEIP - Insider Cow
CNBC View MEIP Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MEIP - OTC Markets
Yahoo View Insider Transactions for MEIP - Yahoo! Finance NASDAQ View Institutional Holdings for MEIP - NASDAQ


Stock Charts

FinViz View MEIP Stock Insight & Charts - FinViz.com StockCharts View MEIP Investment Charts - StockCharts.com
BarChart View MEIP Stock Overview & Charts - BarChart Trading View View MEIP User Generated Charts - Trading View




Latest Financial News for MEIP


MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
Posted on Thursday April 11, 2024

SAN DIEGO, April 11, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that the Company’s Board of Directors unanimously agreed on a strategic plan to leverage recent positive voruciclib and ME-344 clinical data to prioritize clinical development of voruciclib while enabling development of a new ME-344 formulation for Phase 1 study. Additionall


MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
Posted on Thursday April 11, 2024

SAN DIEGO, April 11, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that 25% of evaluable patients with relapsed metastatic colorectal cancer ("mCRC") in Cohort 1 of the ongoing Phase 1b study evaluating ME-344, an investigational inhibitor of mitochondrial oxidative phosphorylation ("OXPHOS"), in combination with bevacizumab (Avastin®) had


MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Posted on Wednesday April 10, 2024

SAN DIEGO, April 10, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16 at 1:30 PM Eastern Time.


MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
Posted on Tuesday March 26, 2024

SAN DIEGO, March 26, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported initiation of enrollment in a 12-patient expansion cohort in the ongoing Phase 1 study evaluating voruciclib, an investigational selective oral cyclin-dependent kinase 9 ("CDK9") inhibitor, in combination with venetoclax (Venclexta®), a B-cell lymphoma 2 ("BCL2") inhibitor,


Stock Market & Investing Books

Enter a stock symbol to view the stock details.